These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Osteoporosis drugs. Current and future options. Mayo Clin Health Lett; 2012 Nov; 30(11):7. PubMed ID: 23795362 [No Abstract] [Full Text] [Related]
24. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Marie PJ; Kassem M Eur J Endocrinol; 2011 Jul; 165(1):1-10. PubMed ID: 21543379 [TBL] [Abstract][Full Text] [Related]
25. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis. Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908 [TBL] [Abstract][Full Text] [Related]
26. [Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases]. Fukumoto S Clin Calcium; 2014 Nov; 24(11):1701-5. PubMed ID: 25355155 [TBL] [Abstract][Full Text] [Related]
27. Anabolic Therapy for the Treatment of Osteoporosis in Childhood. Ward LM; Rauch F Curr Osteoporos Rep; 2018 Jun; 16(3):269-276. PubMed ID: 29589203 [TBL] [Abstract][Full Text] [Related]
28. Anabolic agents: what is beyond osteoporosis? Liu Y; Levack AE; Marty E; Or O; Samuels BP; Redko M; Lane JM Osteoporos Int; 2018 May; 29(5):1009-1022. PubMed ID: 29627891 [TBL] [Abstract][Full Text] [Related]
29. Combination anabolic and antiresorptive therapy for osteoporosis. Cusano NE; Bilezikian JP Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434 [TBL] [Abstract][Full Text] [Related]
30. The use of parathyroid hormone in the treatment of osteoporosis. Girotra M; Rubin MR; Bilezikian JP Rev Endocr Metab Disord; 2006 Jun; 7(1-2):113-21. PubMed ID: 17043762 [TBL] [Abstract][Full Text] [Related]
31. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Brixen KT; Christensen PM; Ejersted C; Langdahl BL Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497 [TBL] [Abstract][Full Text] [Related]
32. [Novel strategies for the development of anabolic agents for treatment of osteoporosis]. Saeki M; Egusa H Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):277-80. PubMed ID: 25492363 [No Abstract] [Full Text] [Related]
33. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis]. Marumo K; Saito M Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369 [TBL] [Abstract][Full Text] [Related]
34. Anabolic therapies for osteoporosis. Farooki A; Fornier M; Girotra M N Engl J Med; 2007 Dec; 357(23):2410-1. PubMed ID: 18057350 [No Abstract] [Full Text] [Related]
35. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis]. Ikeda K; Fukagawa M Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664 [No Abstract] [Full Text] [Related]
36. Changes in the degree of mineralization with osteoporosis and its treatment. Roschger P; Misof B; Paschalis E; Fratzl P; Klaushofer K Curr Osteoporos Rep; 2014 Sep; 12(3):338-50. PubMed ID: 24947951 [TBL] [Abstract][Full Text] [Related]